The Supreme Court on Monday temporarily restored broad access to the abortion pill mifepristone, blocking a lower-court ruling that had restricted how the medication can be prescribed and distributed. Justice Samuel Alito signed the order that allows women to continue obtaining the pill through telehealth consultations, mail delivery, and pharmacies without requiring in-person doctor visits.

The temporary order comes after a federal appeals court last week imposed new restrictions on mifepristone access, threatening to disrupt one of the most common methods of abortion in the United States. The Supreme Court's intervention will remain in effect for at least another week while both sides file responses and the high court considers the case more thoroughly.

Mifepristone, approved by the Food and Drug Administration 25 years ago, is used in the majority of U.S. abortions. The drug is typically taken with misoprostol in a two-drug combination that the FDA says completes medical abortion 97.4% of the time. Louisiana filed the underlying lawsuit challenging FDA rules on mifepristone prescriptions, arguing the policies undermine the state's abortion ban and questioning the drug's safety despite repeated FDA determinations that it is safe and effective.

The legal uncertainty has created operational challenges for abortion providers. Several telehealth organizations switched to prescribing only misoprostol over the weekend before Monday's Supreme Court order allowed them to resume the two-drug regimen. Dr. Angel Foster of The Massachusetts Abortion Access Project said her organization was prepared to send misoprostol-only prescriptions but was able to switch back to the standard combination after the court's decision.

The case has thrust abortion access back into political focus ahead of upcoming midterm elections. Democratic strategists view the legal volatility as potentially motivating voters who support abortion rights, while some anti-abortion groups have criticized Republican leadership for not moving faster to restrict medication abortion access. Public polling shows about two-thirds of Americans oppose nationwide bans on mifepristone, with Republicans more divided on the issue than Democrats and independents.